




July 29, 2020

Contact: Mark Markley markmarkley@searchtech.com

# BizInt Solutions and Search Technology Publish COVID-19 Bullseye Graphic to Aid Understanding of Vaccine Progress

VantagePoint – Smart Charts Edition (VP-SCE) and BizInt Smart Charts software tools used to map vaccine development by clinical trial phase, type of vaccine technology, and lead organization

Seattle, WA – (July 29, 2020) - BizInt Solutions, Inc., and Search Technology, Inc., have published a COVID-19 vaccine 'bullseye' visualization to support analysis of the ever-changing, complex landscape of vaccine development. View the latest COVID-19 Bullseye at <a href="https://www.bizint.com/COVID">www.bizint.com/COVID</a>.



The VP-SCE Bullseye<sup>SM</sup> for COVID-19 vaccines uses data from clinicaltrials.gov, expert analysis, and the companies' powerful data analysis and visualization software tools to populate a bullseye-styled graphic, following leading contenders from Phase 1 clinical trials to launch. The COVID-19 Bullseye provides an 'at-a-glance' review of the vaccine landscape – showing the highest trial phase, vaccine technology, and lead organization for each vaccine.

## How we created the COVID-19 Vaccine Landscape Bullseye

The COVID-19 Bullseye was built with data from the National Institutes of Health (NIH) site, clinicaltrials.gov, using the link on the homepage for "clinical studies related to the coronavirus disease (COVID-19)." The first search was conducted in early July 2020.

Search results were exported from ClinicalTrials.gov in XML into the BizInt Smart Charts Drug Development Suite software to automatically create a formatted, tabular view to support expert analysis. Tools in BizInt Smart Charts and VantagePoint - Smart Charts Edition (VP-SCE) were used to identify vaccine trials from the full set of trial records, review drug and sponsor information to select a single drug name and sponsor(s) for each vaccine, and assign a vaccine technology based on analysis of other publicly available information.

VantagePoint - Smart Charts Edition (VP-SCE) was used to automatically build the VP-SCE Bullseye visualization for the COVID-19 Vaccine Landscape, placing each vaccine according to the most advanced clinical trial phase and vaccine technology. Each vaccine is labeled with the drug name and lead organization(s). On the bullseye, vaccines where clinicaltrials.gov lists trials only in the U.S. are marked with an American flag. More detailed information on the COVID-19 Vaccine Landscape Bullseye is available at <a href="https://www.bizint.com/COVID">www.bizint.com/COVID</a>.

To track the rapidly changing vaccine landscape, the COVID-19 Bullseye will be updated at least every two weeks. BizInt intends to build additional visualizations using the COVID-19 vaccine dataset.

### About VantagePoint—BizInt Smart Charts Edition

VantagePoint – BizInt Smart Charts Edition (VP-SCE) is a custom version of the VantagePoint software designed for use with BizInt Smart Charts. It provides powerful features for data cleanup and filtering multi-database reports, and unique, custom visualizations targeted at drug pipeline and clinical trial analysis.

#### **About BizInt Smart Charts**

BizInt Solutions, Inc. has over 25 years of experience developing BizInt Smart Charts software to help pharmaceutical and biotechnology companies in the U.S., Europe and Asia make better use of industry drug pipeline and clinical trial databases. Our BizDash service combines our expertise in software development, pharmaceutical drug development, information analysis, and graphic design to create competitive intelligence reports and compelling visualizations from global drug pipeline, clinical trial, patent, and IP sequence databases. Learn more at <a href="https://www.bizint.com">www.bizint.com</a>.

### **About Search Technology**

Since 2000, Search Technology's VantagePoint text mining software has provided deep, source-neutral analytics for patent professionals to facilitate technology landscapes, competitive technical intelligence, and portfolio analysis. Learn more at <a href="https://www.TheVantagePoint.com">www.TheVantagePoint.com</a>.